Poor
Needs Revision
Patient Risk:
High
Summary
Several mechanistic, efficacy, adverse reaction, and safety claims are not supported by the provided label excerpts and include multiple material inaccuracies (e.g., dosing interval/duration, intraocular pressure/orbital volume outcomes, and rarity/eye-complication specifics). Indication and some mechanism aspects are partially aligned, but overall alignment is poor.
Category Scores
Accurate Statements
Tepezza (teprotumumab-trbw) is a recombinant human monoclonal antibody that targets the IGF-1 receptor.
Supported by provided label mechanism: Teprotumumab-trbw binds to IGF-1R and blocks its activation and signaling (12.1).
Tepezza inhibits activation of the IGF-1 receptor.
Teprotumumab-trbw binds to IGF-1R and blocks its activation and signaling (12.1).
Tepezza is a monoclonal antibody targeting a specific molecular pathway involved in TED.
Mechanism of action describes IGF-1R binding/blocking signaling (12.1) and the indication is for TED (1).
OPU-102 was a phase 3 trial involving 44 patients with moderate to severe TED.
Not supported by the provided label excerpts.
There is a risk of eye-related complications with tepezza.
Not supported by the provided label excerpts (no eye-related complication risk described in provided text).
Unsupported Statements
In thyroid eye disease (TED), the IGF-1 receptor promotes growth and activity of orbital fibroblasts.
Not supported by provided label excerpts.
In TED, orbital fibroblasts can lead to tissue expansion and compression of the eye.
Not supported by provided label excerpts.
By inhibiting the IGF-1 receptor, tepezza reduces proliferation and activation of orbital fibroblasts.
Not supported by provided label excerpts.
Reducing proliferation and activation of orbital fibroblasts by tepezza leads to a decrease in intraocular pressure.
Not supported by provided label excerpts.
Reducing proliferation and activation of orbital fibroblasts by tepezza leads to a decrease in orbital volume.
Not supported by provided label excerpts.
Tepezza is administered intravenously every four weeks for up to 17 months.
Contradicts provided dosing schedule (20 mg/kg every three weeks for 7 additional infusions); not supported by label.
OPU-102 was a phase 3 trial involving 44 patients with moderate to severe TED.
Not supported by provided label excerpts.
In the OPU-102 trial, tepezza produced significant improvements in orbital disease activity.
Not supported by provided label excerpts.
In the OPU-102 trial, tepezza produced significant improvements in inflammation.
Not supported by provided label excerpts.
In the OPU-102 trial, tepezza produced significant improvements in eye motility scores.
Not supported by provided label excerpts.
Common adverse reactions to tepezza include skin rash.
The provided label excerpts do not list skin rash as a common adverse reaction (Table 1 not provided).
Common adverse reactions to tepezza include pruritus.
The provided label excerpts do not list pruritus as a common adverse reaction (Table 1 not provided).
Common adverse reactions to tepezza include fatigue.
The provided label excerpts do not list fatigue as a common adverse reaction (Table 1 not provided).
Eye-related complications with tepezza include optic neuropathy.
Not supported by provided label excerpts; postmarketing otologic hearing impairment is described, not optic neuropathy.
Eye-related complications with tepezza include increased intraocular pressure.
Not supported by provided label excerpts.
Optic neuropathy and increased intraocular pressure are relatively rare with tepezza.
Not supported by provided label excerpts.
The patent for tepezza expires in 2029.
Not supported by provided label excerpts.
After patent expiry, biosimilar competition may emerge.
Not supported by provided label excerpts.
Tepezza is administered intravenously every four weeks for up to 17 months.
Not supported; label dosing is every three weeks for 7 additional infusions (2.1) and total 8 infusions (14).
Contradictions
High
AI Statement
Tepezza is administered intravenously every four weeks for up to 17 months.
Label Reference
Recommended dosing: initial 10 mg/kg then 20 mg/kg every three weeks for 7 additional infusions (2.1). Clinical studies: every 3 weeks for a total of 8 infusions (14).
Important Omissions
Label dosing and administration details: 10 mg/kg initial then 20 mg/kg every 3 weeks for 7 additional infusions; infusion over at least 90 minutes for first two infusions (then 60 minutes if well tolerated); do not administer IV push/bolus; not concurrently with other agents.
Importance:
High
Key safety precautions from provided label: infusion reactions, inflammatory bowel disease exacerbation, hyperglycemia monitoring, and hearing impairment assessment before/during/after treatment.
Importance:
Moderate
Pregnancy contraindication/use restriction described in provided label: TEPEZZA should not be used in pregnancy and contraception for 6 months after last dose.
Importance:
Moderate
Drug interaction evidence: label states no drug interaction studies have been conducted.
Importance:
Low
Safety Assessment
Potential Patient Risk:
High
Material mismatch in dosing interval/duration (every 4 weeks up to 17 months vs label every 3 weeks for 7 additional infusions) plus unsupported eye-complication specifics and unsupported common adverse reactions create high risk of misinformation relative to the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Incorrect dosing schedule and multiple safety/outcome claims are not supported by the provided FDA label excerpts.
Suggested Improvement
Replace dosing and administration with label text (10 mg/kg initial, then 20 mg/kg every 3 weeks for 7 additional infusions; infusion duration; do not push/bolus; avoid concomitant infusion with other agents). Remove or reframe unsupported mechanistic, efficacy (OPU-102 outcomes), adverse reaction frequency (skin rash/pruritus/fatigue), and eye-complication specifics (optic neuropathy, increased intraocular pressure, rarity) unless supported by the provided label. Include label warnings/precautions (infusion reactions, IBD, hyperglycemia, hearing impairment) and pregnancy restriction if relevant.